)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Agios Pharmaceuticals (AGIO) investor relations material
Agios Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary30 Oct, 2025
Executive summary
Achieved $12.9 million in net revenue for Q3 2025, up 44% year-over-year and 3% sequentially, driven by PYRUKYND commercial execution in rare hematologic diseases.
Net loss of $103.4 million in Q3 2025, compared to net income of $947.9 million in Q3 2024, which included significant one-time milestone and royalty payments.
Maintains strong financial position with $1.3 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, supporting commercial launches and pipeline investments.
Advanced regulatory milestones for PYRUKYND in thalassemia, including approval in Saudi Arabia, positive CHMP opinion in Europe, and ongoing FDA review with a PDUFA date of December 7, 2025.
Pipeline momentum with completed enrollment in phase II-B tebapivat trial for lower-risk MDS; topline data expected early 2026.
Financial highlights
Q3 2025 net revenue was $12.9 million, up from $9.0 million in Q3 2024 and $12.5 million in Q2 2025.
Net loss for Q3 2025 was $103.4 million, compared to net income of $947.9 million in Q3 2024, which included $889.1 million from the sale of royalty rights and a $200 million milestone payment.
R&D expenses rose to $86.8 million, up from $72.5 million year-over-year, mainly due to increased clinical trial costs.
SG&A expenses were $41.3 million, up from $38.5 million in Q3 2024, reflecting investments for potential U.S. launch.
Cash, cash equivalents, and marketable securities at $1.3 billion at Q3 2025, down from $1.5 billion at Q4 2024.
Outlook and guidance
Anticipates robust net revenue growth for 2025, with multiple high-value catalysts including potential FDA approval for PYRUKYND in thalassemia (PDUFA date December 7, 2025) and Phase 3 RISE UP data in SCD by year-end.
Topline results from the phase II-B tebapivat trial in lower-risk MDS expected in early 2026.
Ongoing launch preparations in the U.S., Europe, and GCC for thalassemia indications.
Cash position expected to fund operations for at least the next twelve months.
Anticipates increased expenses as clinical and commercial activities expand, especially for PYRUKYND in thalassemia and SCD.
Detail the expected REMS program for PYRUKYND
What are the key success criteria for RISE UP?
Tebapivat LR-MDS: What defines positive data?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Agios Pharmaceuticals earnings date
Q4 202512 Feb, 2026
Next Agios Pharmaceuticals earnings date
Q4 202512 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Agios Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering and developing therapies for genetically defined diseases. The company leverages its expertise in cellular metabolism and genetic pathways to create treatments for rare and severe conditions, including metabolic and hematologic disorders. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage